1.Effects of Shengmai Decoction on postoperative recovery and the anxiety and depression in breast cancer patients
Huilong REN ; Yukun WANG ; Simiao YAO ; Kai XU ; Guokai LIU ; Chao DING
Cancer Research and Clinic 2025;37(5):366-370
Objective:To investigate the effects of Shengmai Decoction on postoperative recovery and the anxiety and depression in breast cancer patients after surgery.Methods:A prospective randomized controlled study was conducted. A total of 60 patients with breast cancer after operation in Dongzhimen Hospital, Beijing University of Chinese Medicine from October 2023 to July 2024 were selected, and all patients were divided into the Shengmai Decoction group and the control group according to the random number table method with 30 cases in each group. The Shengmai Decoction group was given the Shengmai Decoction 3 times per day (10 ml each time before meals) with continuous treatment for 7 d, and the patients in the control group drank 10 ml of water at the same time point. The scores of 40-item quality of recovery (QoR-40), traditional Chinese medicine syndrome, Pittsburgh sleep quality index (PSQI), self-rating anxiety scale (SAS), self-rating depression scale (SDS) before treatment and 7 d after treatment were compared and adverse reactions of the 2 groups were recorded.Results:All patients were female. In the Shengmai Decoction group, 17 patients (56.7%) underwent modified radical mastectomy and 13 patients (43.3%) underwent breast-conserving surgery with the age of (48±12) years; in the control group, 16 patients (53.3%) underwent modified radical mastectomy and 14 patients (46.7%) underwent breast-conserving surgery with the age of (51±12) years. There were no statistically significant differences in age, body mass index, surgery type, menopause, operation time, intraoperative blood loss and between the 2 groups (all P > 0.05). The difference in QoR-40 score before treatment between the 2 groups was not statistically significant ( P > 0.05). The emotional state score [(41.0±1.8) points vs. (38.0±2.7) points], psychological support score [(32.6±1.4) points vs. (30.3±1.5) points], and total score [(178.7±3.4) points vs. (170.1±3.9) points] of QoR-40 score in the Shengmai Decoction group were higher than those in the control group 7 d after treatment, and the differences were statistically significant ( t value was 5.21, 6.01, 9.04, all P < 0.05). The differences in the scores of traditional Chinese medicine syndrome, PSQI, SAS and SDS of both groups before treatment were not statistically significant (all P > 0.05). The scores of traditional Chinese medicine syndrome, PSQI, SAS and SDS of both groups 7 d after treatment were decreased compared with those before treatment, and the scores in the Shengmai Decoction group were lower than those in the control group, and the differences were statistically significant (all P < 0.05). The incidence of adverse reactions was 15.0% (2/30) and 10.0% (3/30) in the Shengmai Decoction group and the control group, respectively, and the difference was not statistically significant ( P > 0.05). Conclusions:Shengmai Decoction can enhance the postoperative sleep quality, improve anxiety and depression as well as the quality of postoperative recovery in patients with breast cancer.
2.New insights and prospects of drug-induced liver injury in the context of chronic cholestatic liver diseases
Simiao YU ; Jiabo WANG ; Xiaohe XIAO ; Ruilin WANG
Journal of Clinical Hepatology 2025;41(2):365-369
Patients with chronic cholestatic liver diseases face numerous challenges in the detection, assessment, and management of suspected drug-induced liver injury (DILI), and in particular, it is difficult to distinguish cholestatic DILI from the progression of underlying cholestatic liver diseases clinically and histologically. Currently, there is a lack of related research and management guidelines for DILI with chronic cholestatic liver diseases. This article discusses the potential risks, causality, and classification criteria for chronic cholestatic liver diseases with DILI, in order to improve the understanding of such diseases among clinicians and provide a reference for prevention, treatment, and management strategies.
3.The Effect of Fuzheng Huaji Formula (扶正化积方) for Chronic Hepatitis B on Reduction of the Incidence of Liver Cirrhosis and Hepatocellular Carcinoma:A Retrospective Cohort Study
Simiao YU ; Jiahui LI ; Jing JING ; Tingting HE ; Yongqiang SUN ; Liping WANG ; Aozhe ZHANG ; Xiaohe XIAO ; Xia DING ; Ruilin WANG
Journal of Traditional Chinese Medicine 2025;66(3):268-274
ObjectiveTo evaluate the clinical efficacy of Fuzheng Huaji Formula (扶正化积方) for chronic hepatitis B to reduce the incidence of liver cirrhosis and hepatocellular carcinoma. MethodsA retrospective cohort study was conducted, collecting medical records of 118 patients with chronic hepatitis B and 234 patients with hepatitis B-related cirrhosis who visited the hospital between January 1, 2014, and December 31, 2018. The use of Fuzheng Huaji Formula was designated as the exposure factor. Patients receiving antiviral treatment for hepatitis B without concurrent Fuzheng Huaji Formula therapy were included in the western medicine group, while those receiving antiviral treatment combined with Fuzheng Huaji Formula for a cumulative treatment lasting longer than 3 months were included in the combined treatment group. The follow-up observation period was five years. Kaplan-Meier survival analysis was used to assess the cumulative incidence of cirrhosis in patients with chronic hepatitis B and the cumulative incidence of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis. Univariate and multivariate Cox regression analyses were employed to examine the factors influencing the occurrence of cirrhosis and hepatocellular carcinoma. ResultsAmong patients with chronic hepatitis B, there were 55 cases in the combined treatment group and 63 cases in the western medicine group; among patients with hepatitis B-related cirrhosis, there were 110 cases in the combined treatment group and 124 cases in the western medicine group. Five-year follow-up outcomes for chronic hepatitis B patients showed that the cumulative incidence of cirrhosis was 5.45% (3/55) in the combined treatment group and 17.46% (11/63) in the western medicine group, with a statistically significant difference between groups (Z = 2.003, P = 0.045). Five-year follow-up outcomes for hepatitis B-related cirrhosis patients showed that the cumulative incidence of hepatocellular carcinoma was 8.18% (9/110) in the combined treatment group and 22.58% (28/124) in the western medicine group, also showing a statistically significant difference (Z = 3.007, P = 0.003). Univariate and multivariate Cox regression analyses indicated that treatment with Fuzheng Huaji Formula is an independent protective factor in preventing the progression of chronic hepatitis B to cirrhosis and the progression of hepatitis B-related cirrhosis to hepatocellular carcinoma (P<0.05). ConclusionCombining Fuzheng Huaji Formula with antiviral therapy for hepatitis B can effectively intervene in the disease progression of chronic hepatitis B, reducing the incidence of cirrhosis and hepatocellular carcinoma.
4.Research advances in traditional Chinese medicine for the prevention and treatment of inflammation-to-cancer transformation in chronic hepatitis
Simiao YU ; Sici WANG ; Haocheng ZHENG ; Yongqiang SUN ; Jing JING ; Tingting HE ; Liping WANG ; Aozhe ZHANG ; Xin WANG ; Xia DING ; Ruilin WANG
Journal of Clinical Hepatology 2025;41(9):1888-1895
Primary liver cancer is one of the most common malignant tumors of the digestive system, and the “inflammation-to-cancer transformation” (ICT) of chronic hepatitis is the core pathological process of the progression of chronic hepatitis to liver cancer. Persistent and uncontrolled liver inflammation in patients with chronic hepatitis often leads to repeated liver tissue damage and repair, which gradually develops into liver fibrosis and cirrhosis, eventually leading to malignant transformation through the mechanisms such as gene mutation and microenvironment imbalance. ICT in chronic hepatitis is the key link between chronic hepatitis and liver cancer, and its dynamic evolution involves various pathogenic factors such as dampness, heat, deficiency, toxin, and stasis; among which damp-heat and vital energy deficiency are the initiating factors for ICT of chronic hepatitis, while intermingled stasis and toxin are the key pathological products that promote malignant transformation. Based on the concept of preventive treatment, traditional Chinese medicine can effectively delay and even block the ICT of chronic hepatitis by regulating inflammation, metabolism, and abnormal cell proliferation through multiple targets, which provides important strategies and research directions for the prevention and treatment of liver cancer.
5.LIU Zhibin's experience in treatment of subjective tinnitus with acupuncture based on the "kidney-bone-brain" axis.
Yunru WU ; Zhibin LIU ; Weixing FENG ; Weigang WANG ; Enzhao FAN ; Yanbin YAN
Chinese Acupuncture & Moxibustion 2025;45(6):808-812
This paper introduces Professor LIU Zhibin 's clinical experience in the treatment of subjective tinnitus with acupuncture based on the "kidney-bone-brain" axis. Professor LIU proposes that the disease is most closely related to the kidney and brain. The lesion is located in the brain, and the pathogenesis is kidney essence deficiency, marrow sea loss, and ear orifice dystrophy. The "kidney-bone-brain" shows close correlation in physiological function, pathological changes and treatment. According to the "kidney-bone-brain" axis, Professor LIU proposes that the treatment of subjective tinnitus should be tonifying kidney qi, tonifying essence and filling marrow, and the principle of local acupoint selection, touching bone acupuncture, matching distal acupoints and proximal acupoints, tonifying kidney and benefiting brain should be adopted. The acupoints of Tinggong (SI19) and Yifeng (TE17) are selected to be treated with touching bone acupuncture, combined with Taixi (KI3), Shenshu (BL23), Baihui (GV20) and Shenting (GV24), so as to achieve common benefit of kidney, bone and brain, and multi-angle treatment.
Humans
;
Acupuncture Therapy/history*
;
Tinnitus/physiopathology*
;
Acupuncture Points
;
Kidney/physiopathology*
;
Brain/physiopathology*
;
Bone and Bones/physiopathology*
;
Female
;
Male
;
Adult
;
Middle Aged
6.Clinical course, causes of worsening, and outcomes of severe ischemic stroke: A prospective multicenter cohort study.
Simiao WU ; Yanan WANG ; Ruozhen YUAN ; Meng LIU ; Xing HUA ; Linrui HUANG ; Fuqiang GUO ; Dongdong YANG ; Zuoxiao LI ; Bihua WU ; Chun WANG ; Jingfeng DUAN ; Tianjin LING ; Hao ZHANG ; Shihong ZHANG ; Bo WU ; Cairong ZHU ; Craig S ANDERSON ; Ming LIU
Chinese Medical Journal 2025;138(13):1578-1586
BACKGROUND:
Severe stroke has high rates of mortality and morbidity. This study aimed to investigate the clinical course, causes of worsening, and outcomes of severe ischemic stroke.
METHODS:
This prospective, multicenter cohort study enrolled adult patients admitted ≤30 days after ischemic stroke from nine hospitals in China between September 2017 and December 2019. Severe stroke was defined as a score of ≥15 on the National Institutes of Health Stroke Scale (NIHSS). Clinical worsening was defined as an increase of 4 in the NIHSS score from baseline. Unfavorable functional outcome was defined as a modified Rankin scale score ≥3 at 3 months and 1 year after stroke onset, respectively. We performed Logistic regression to explore baseline features and reperfusion therapies associated with clinical worsening and functional outcomes.
RESULTS:
Among 4201 patients enrolled, 854 patients (20.33%) had severe stroke on admission. Of 3347 patients without severe stroke on admission, 142 (4.24%) patients developed severe stroke in hospital. Of 854 patients with severe stroke on admission, 33.95% (290/854) experienced clinical worsening (median time from stroke onset: 43 h, Q1-Q3: 20-88 h), with brain edema (54.83% [159/290]) as the leading cause; 24.59% (210/854) of these patients died by 30 days, and 81.47% (677/831) and 78.44% (633/807) had unfavorable functional outcomes at 3 months and 1 year respectively. Reperfusion reduced the risk of worsening (adjusted odds ratio [OR]: 0.24, 95% confidence interval [CI]: 0.12-0.49, P <0.01), 30-day death (adjusted OR: 0.22, 95% CI: 0.11-0.41, P <0.01), and unfavorable functional outcomes at 3 months (adjusted OR: 0.24, 95% CI: 0.08-0.68, P <0.01) and 1 year (adjusted OR: 0.17, 95% CI: 0.06-0.50, P <0.01).
CONCLUSIONS:
Approximately one-fifth of patients with ischemic stroke had severe neurological deficits on admission. Clinical worsening mainly occurred in the first 3 to 4 days after stroke onset, with brain edema as the leading cause of worsening. Reperfusion reduced the risk of clinical worsening and improved functional outcomes.
REGISTRATION
ClinicalTrials.gov , NCT03222024.
Humans
;
Male
;
Female
;
Prospective Studies
;
Ischemic Stroke/mortality*
;
Aged
;
Middle Aged
;
Aged, 80 and over
;
Stroke
;
Brain Ischemia
7.Promotive effect of high expression of nerve growth factor in Schwan-like cells induced by adipose-derived stem cells on growth of rat dorsal root ganglion cell protrusion
Qinghua ZHU ; Bo YUAN ; Yilun WANG ; Miao REN ; Xiaofei LI ; Simiao WANG ; Zixuan ZHEN ; Xiumei FU
Journal of Jilin University(Medicine Edition) 2025;51(4):984-995
Objective:To discuss the promotive effect of nerve growth factor(NGF),which is highly expressed in the adipose-derived stem cell(ADSC)-induced Schwann-like cells(SCLCs),on the growth of dorsal root ganglion(DRG)cell processes in the rats,and to clarify its mechanism.Methods:The ADSCs were extracted from the epididymal adipose tissue of the SD rats,and their multidirectional differentiation potential was identified through osteogenic,adipogenic,and chondrogenic induction.The ADSCs were induced to differentiate into the SCLCs,and the expression levels of glial fibrillary acidic protein(GFAP)and S100 calcium-binding protein β(S100β)protein in the ADSCs and SCLCs were detected by immunofluorescence staining and Western blotting methods.The DRG cells were isolated and cultured,and immunofluorescence staining was used to detect the βⅢ-tubulin expression in the DRG cells for identification.The SCLCs were co-cultured with the DRG cells(co-culture group),the single-culture DRG cells were regared as DRG group and toluidine blue staining was used to observe and measure the length of DRG cell processes under the optical microscope in co-culture group and DRG group.Small interfering RNA(siRNA)transfection was used to knock down NGF,and plasmid transfection was used to over-express NGF.Real-time fluorescence quantitative PCR(RT-qPCR)method was used to detect the NGF mRNA expression levels in the cells in various groups;enzyme-linked immunosorbent assay(ELISA)method was used to detect the NGF protein levels in the cell supernatants.The transfected SCLCs were co-cultured with DRG cells and divided into control group,siNC/vector group,NGF knockdown group(si-NGF group),and NGF over-expression group(oe-NGF group).The lengths of DRG cell processes in various groups were observed.Results:The primary ADSCs adhered within 24 h after seeding,with a small number of lipid droplets remaining.After 3 d of culture,the cells were mostly short spindle-shaped,fusiform,or polygonal,growing rapidly in a vortex pattern.After passaging,the cells exhibited a uniform morphology,appearing as long spindles arranged in a fish-school pattern.After 14 d of adipogenic induction,the cell morphology changed from spindle-shaped to flat-round,with translucent lipid droplets forming in the cytoplasm,which were stained red by Oil Red O.After 28 d of osteogenic induction,the cells appeared sand-like with blurred morphology,and calcified nodules were observed,which were stained red by Alizarin Red and deposited in the extracellular matrix.After 28 d of chondrogenic induction in a 3D culture system,millet-sized chondrogenic spheres formed.Frozen sections of the spheres were stained with Alcian Blue,and acidic mucopolysaccharides in the cartilage tissue were stained blue under the microscope.Under the fluorescence microscope,the third-passage purified ADSCs showed positive expression of CD29[fluorescein isothiocy anate(FITC)-labeled green fluorescence]and CD44(Cy3-labeled red fluorescence).The immunofluorescence staining results showed that GFAP was labeled with FITC(green fluorescence),and S100β was labeled with Cy3(red fluorescence).The Western blotting results showed that compared with ADSCs,the expression levels of S100β and GFAP proteins in the SCLCs were increased(P<0.05).The primary DRG cells began to adhere 6 h after conventional culture,and after 3 d,the cell bodies appeared round and bright,with two linear processes extending from them.Under fluorescence microscope,the cells positively expressed the neuron-specific marker βⅢ-tubulin,confirming that the isolated cells were DRG cells.Compared with the ADSCs,the NGF protein expression level in the SCLCs was increased(P<0.05).Compared with DRG group,the length of DRG cell processes in co-culture group was the highest when DRG cells and SCLCs were co-cultured at a 1∶2 ratio(P<0.05).The RT-qPCR results showed that compared with si-NC group,the expression levels of NGF mRNA in the cell supernatant in si-NGF-1,si-NGF-2,and si-NGF-3 groups were significantly decreased(P<0.05),with si-NGF-1 showing the highest knockdown efficiency,which was selected for subsequent experiments.The ELISA results showed that compared with si-NC group,the NGF levels in the cell supernatant of si-NGF-1,si-NGF-2,and si-NGF-3 groups were decreased(P<0.05).Compared with Vector group,the expression level of NGF mRNA and NGF protein level in the supernatant in oe-NGF group were increased(P<0.05).Compared with control group and siNC/vector group,the length of DRG cell processes in si-NGF group was decreased(P<0.05),while the length of DRG cell processes in oe-NGF group was increased(P<0.05).Conclusion:ADSCs can be directionally differentiated into SCLCs,and the differentiated cells highly express NGF.Knockdown or overexpression of NGF can affect the growth of DRG cell processes.
8.Practice of establishing a"6+1"homogenization management system for outpatient services:a case study of a tertiary general hospital in Guangdong province
Xuan ZHONG ; Xiaowen MAI ; Minyi WANG ; Zhimin HE ; Qichang WU ; Simiao WANG ; Hao WANG ; Xun ZENG ; Ming ZHAO ; Dayue LIU
Modern Hospital 2025;25(4):534-536,540
This study aims to innovate a homogeneous outpatient service management system across multiple hospital campuses to enhance service quality.Based on the practical experience of a tertiary general hospital in Guangdong Province and in accordance with the"Interim Regulations on Outpatient Quality Management in Healthcare Institutions,"we constructed a"6+1"homogeneous outpatient service management system.This system includes:① a multi-stakeholder co-governance outpa-tient management system,②a vertical and cross-hierarchical management network,③ a democratic-centralized clinical coordina-tion strategy,④ a guidance-encouragement performance evaluation standard,⑤a collaborative dynamic supervision mechanism,⑥a spiral retrospective evaluation and improvement method,and ⑦ an integrated outpatient diagnosis and treatment system.Af-ter over two years of implementation,the hospital's outpatient volume has grown by an average of over 15%annually,patient waiting time after appointment has been reduced to 20 minutes,and patient satisfaction in the tertiary public hospital performance evaluation achieved full marks.The electronic medical record system functionality reached Level 6,significantly improving healthcare service efficiency and quality while enhancing homogeneous management across campuses.
9.Practice of establishing a"6+1"homogenization management system for outpatient services:a case study of a tertiary general hospital in Guangdong province
Xuan ZHONG ; Xiaowen MAI ; Minyi WANG ; Zhimin HE ; Qichang WU ; Simiao WANG ; Hao WANG ; Xun ZENG ; Ming ZHAO ; Dayue LIU
Modern Hospital 2025;25(4):534-536,540
This study aims to innovate a homogeneous outpatient service management system across multiple hospital campuses to enhance service quality.Based on the practical experience of a tertiary general hospital in Guangdong Province and in accordance with the"Interim Regulations on Outpatient Quality Management in Healthcare Institutions,"we constructed a"6+1"homogeneous outpatient service management system.This system includes:① a multi-stakeholder co-governance outpa-tient management system,②a vertical and cross-hierarchical management network,③ a democratic-centralized clinical coordina-tion strategy,④ a guidance-encouragement performance evaluation standard,⑤a collaborative dynamic supervision mechanism,⑥a spiral retrospective evaluation and improvement method,and ⑦ an integrated outpatient diagnosis and treatment system.Af-ter over two years of implementation,the hospital's outpatient volume has grown by an average of over 15%annually,patient waiting time after appointment has been reduced to 20 minutes,and patient satisfaction in the tertiary public hospital performance evaluation achieved full marks.The electronic medical record system functionality reached Level 6,significantly improving healthcare service efficiency and quality while enhancing homogeneous management across campuses.
10.Effects of Shengmai Decoction on postoperative recovery and the anxiety and depression in breast cancer patients
Huilong REN ; Yukun WANG ; Simiao YAO ; Kai XU ; Guokai LIU ; Chao DING
Cancer Research and Clinic 2025;37(5):366-370
Objective:To investigate the effects of Shengmai Decoction on postoperative recovery and the anxiety and depression in breast cancer patients after surgery.Methods:A prospective randomized controlled study was conducted. A total of 60 patients with breast cancer after operation in Dongzhimen Hospital, Beijing University of Chinese Medicine from October 2023 to July 2024 were selected, and all patients were divided into the Shengmai Decoction group and the control group according to the random number table method with 30 cases in each group. The Shengmai Decoction group was given the Shengmai Decoction 3 times per day (10 ml each time before meals) with continuous treatment for 7 d, and the patients in the control group drank 10 ml of water at the same time point. The scores of 40-item quality of recovery (QoR-40), traditional Chinese medicine syndrome, Pittsburgh sleep quality index (PSQI), self-rating anxiety scale (SAS), self-rating depression scale (SDS) before treatment and 7 d after treatment were compared and adverse reactions of the 2 groups were recorded.Results:All patients were female. In the Shengmai Decoction group, 17 patients (56.7%) underwent modified radical mastectomy and 13 patients (43.3%) underwent breast-conserving surgery with the age of (48±12) years; in the control group, 16 patients (53.3%) underwent modified radical mastectomy and 14 patients (46.7%) underwent breast-conserving surgery with the age of (51±12) years. There were no statistically significant differences in age, body mass index, surgery type, menopause, operation time, intraoperative blood loss and between the 2 groups (all P > 0.05). The difference in QoR-40 score before treatment between the 2 groups was not statistically significant ( P > 0.05). The emotional state score [(41.0±1.8) points vs. (38.0±2.7) points], psychological support score [(32.6±1.4) points vs. (30.3±1.5) points], and total score [(178.7±3.4) points vs. (170.1±3.9) points] of QoR-40 score in the Shengmai Decoction group were higher than those in the control group 7 d after treatment, and the differences were statistically significant ( t value was 5.21, 6.01, 9.04, all P < 0.05). The differences in the scores of traditional Chinese medicine syndrome, PSQI, SAS and SDS of both groups before treatment were not statistically significant (all P > 0.05). The scores of traditional Chinese medicine syndrome, PSQI, SAS and SDS of both groups 7 d after treatment were decreased compared with those before treatment, and the scores in the Shengmai Decoction group were lower than those in the control group, and the differences were statistically significant (all P < 0.05). The incidence of adverse reactions was 15.0% (2/30) and 10.0% (3/30) in the Shengmai Decoction group and the control group, respectively, and the difference was not statistically significant ( P > 0.05). Conclusions:Shengmai Decoction can enhance the postoperative sleep quality, improve anxiety and depression as well as the quality of postoperative recovery in patients with breast cancer.

Result Analysis
Print
Save
E-mail